Keros Therapeutics vs Viridian Therapeutics, Inc.\DE
KROS and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KROS and VRDN compare
Viridian Therapeutics, Inc.\DE is the larger company, worth 15 times as much as Keros Therapeutics ($3.4B against $224M).
Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus −93.7% for Keros Therapeutics).
Viridian Therapeutics, Inc.\DE keeps more of each dollar of sales as profit, with a net margin of −544% compared with −572% at Keros Therapeutics.
Keros Therapeutics scores higher on the StockData Score (7 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KROS | VRDN |
|---|---|---|
| Size and price | ||
| Market cap | $224M | $3.4B |
| Share price | $11.31 | $30.06 |
| Change, 1 year | −34.5% | 4.5% |
| Change, 5 years | −79.8% | 64.3% |
| Beta (5Y) | 2.04 | −0.13 |
| Employees | 78 | 252 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.4× (better) | 47.9× |
| P/B | 0.9× (better) | 5.1× |
| FCF yield | −21.6% | −9.8% (better) |
| Fair value | – | $8.47 |
| Margin of safety | – | −255% |
| Growth | ||
| Revenue growth (TTM) | −93.7% | 23220% (better) |
| Revenue growth, 5Y average | – | 132% |
| Net income growth (TTM) | −543% | – |
| EPS growth (TTM) | −1287% | – |
| Profitability | ||
| Operating margin | −698% | −570% (better) |
| Net margin | −572% | −544% (better) |
| FCF margin | −334% (better) | −471% |
| Return on equity | −17.2% (better) | −65.7% |
| Return on invested capital | −755% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −26.0× |
| Current ratio | 21.96 (better) | 16.95 |
| Altman Z-score | 2.67 (better) | 2.65 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −1.7% |
| Shareholder yield | 0.00% (better) | −1.7% |
| Ownership | ||
| Held by institutions | 101% | 120% |
| Held by insiders | 53.3% | 21.8% |
| Insider net buying, 12 months | −$453K | $19.6M (better) |
| Short interest, % of float | 11.7% | 19.2% |
Go deeper
- KROS stock overview
- KROS income statement
- KROS valuation and score
- VRDN stock overview
- VRDN income statement
- VRDN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.